BACKGROUND: Breast cancer rarely occurs in young women. Our knowledge about disease presentation, prognosis and treatment effects are largely dependent upon older series. MATERIALS AND METHODS: We evaluated biological features and stage at presentation for 1427 consecutive premenopausal patients aged < or = 50 years with first diagnosis of invasive breast cancer referred to surgery at the European Institute of Oncology from April 1997 to August 2000. A total of 185 patients (13%) were aged < 35 years ('very young') and 1242 (87%) were aged 35-50 years ('less young'). The expression of estrogen receptors (ER), progesterone receptors (PgR), presence of vascular invasion (VI), grading (G), expression of Ki-67, HER2/neu overexpression, pathological stage according to TNM staging system (pTNM), pathological tumor size and number of axillary lymph node involvement were evaluated. RESULTS: Compared with less young patients, the very young patient group had a higher percentage of tumors classified as ER negative (P < 0.001), PgR negative (P = 0.001), higher expression of Ki-67 > or = 20% of cells stained; 62.2% versus 53%, (P < 0.001), vascular or lymphatic invasion (48.6% versus 37.3%, P = 0.006), and pathological grade 3 (P < 0.0001). There was no difference between the two groups for pT, pathological tumor size (pN) and number of positive lymph nodes. CONCLUSIONS: We conclude that compared with less young premenopausal patients, very young women have a greater chance of having an endocrine-unresponsive tumor, and are more likely to present with a higher grade, more extensively proliferating and vessel invading disease. Pathological tumor size, nodal status and number of positive axillary lymph-nodes have a similar distribution among the younger and the older cohorts, thus not supporting previous data indicating more advanced disease in younger patients at diagnosis of operable disease.
BACKGROUND:Breast cancer rarely occurs in young women. Our knowledge about disease presentation, prognosis and treatment effects are largely dependent upon older series. MATERIALS AND METHODS: We evaluated biological features and stage at presentation for 1427 consecutive premenopausal patients aged < or = 50 years with first diagnosis of invasive breast cancer referred to surgery at the European Institute of Oncology from April 1997 to August 2000. A total of 185 patients (13%) were aged < 35 years ('very young') and 1242 (87%) were aged 35-50 years ('less young'). The expression of estrogen receptors (ER), progesterone receptors (PgR), presence of vascular invasion (VI), grading (G), expression of Ki-67, HER2/neu overexpression, pathological stage according to TNM staging system (pTNM), pathological tumor size and number of axillary lymph node involvement were evaluated. RESULTS: Compared with less young patients, the very young patient group had a higher percentage of tumors classified as ER negative (P < 0.001), PgR negative (P = 0.001), higher expression of Ki-67 > or = 20% of cells stained; 62.2% versus 53%, (P < 0.001), vascular or lymphatic invasion (48.6% versus 37.3%, P = 0.006), and pathological grade 3 (P < 0.0001). There was no difference between the two groups for pT, pathological tumor size (pN) and number of positive lymph nodes. CONCLUSIONS: We conclude that compared with less young premenopausal patients, very young women have a greater chance of having an endocrine-unresponsive tumor, and are more likely to present with a higher grade, more extensively proliferating and vessel invading disease. Pathological tumor size, nodal status and number of positive axillary lymph-nodes have a similar distribution among the younger and the older cohorts, thus not supporting previous data indicating more advanced disease in younger patients at diagnosis of operable disease.
Authors: Saranya Chumsri; Daniel J Serie; Zhuo Li; Katherine L Pogue-Geile; Aixa E Soyano-Muller; Afshin Mashadi-Hossein; Sarah Warren; Yanyan Lou; Gerardo Colon-Otero; Keith L Knutson; Edith A Perez; Alvaro Moreno-Aspitia; E Aubrey Thompson Journal: Clin Cancer Res Date: 2019-02-26 Impact factor: 12.531
Authors: Mary Regina Boland; George Hripcsak; Yufeng Shen; Wendy K Chung; Chunhua Weng Journal: J Am Med Inform Assoc Date: 2013-09-03 Impact factor: 4.497
Authors: Jennifer K Plichta; Samantha M Thomas; Rebecca Vernon; Oluwadamilola M Fayanju; Laura H Rosenberger; Terry Hyslop; E Shelley Hwang; Rachel A Greenup Journal: Breast Cancer Res Treat Date: 2020-01-24 Impact factor: 4.872
Authors: Maciej Jóźwik; Renata Posmyk; Marcin Jóźwik; Andrzej Semczuk; Magdalena Gogiel-Shields; Marta Kuś-Słowińska; Magdalena Garbowicz; Mark Klukowski; Jacek Wojciechowicz Journal: Cancer Biol Ther Date: 2018-07-03 Impact factor: 4.742
Authors: Winnie Yeo; Hang-Mei Lee; Amy Chan; Emily Yy Chan; Miranda Cm Chan; Keeng-Wai Chan; Sharon Ww Chan; Foon-Yiu Cheung; Polly Sy Cheung; Peter Hk Choi; Josette Sy Chor; William Wl Foo; Wing-Hong Kwan; Stephen Ck Law; Lawrence Pk Li; Janice Wh Tsang; Yuk Tung; Lorna Ls Wong; Ting-Ting Wong; Chun-Chung Yau; Tsz-Kok Yau; Benny Cy Zee Journal: World J Clin Oncol Date: 2014-12-10
Authors: Hanna Fredholm; Sonja Eaker; Jan Frisell; Lars Holmberg; Irma Fredriksson; Henrik Lindman Journal: PLoS One Date: 2009-11-11 Impact factor: 3.240